Free Trial
NASDAQ:KLDO

Kaleido Biosciences (KLDO) Stock Price, News & Analysis

Kaleido Biosciences logo

About Kaleido Biosciences Stock (NASDAQ:KLDO)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
330 shs
Average Volume
3,238 shs
Market Capitalization
$6.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Receive KLDO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kaleido Biosciences and its competitors with MarketBeat's FREE daily newsletter.

KLDO Stock News Headlines

Download Our Tesla Ebook For Free
Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.
Kaleido Biosciences (OTC: KLDO)
See More Headlines

KLDO Stock Analysis - Frequently Asked Questions

Kaleido Biosciences, Inc. (NASDAQ:KLDO) issued its earnings results on Monday, November, 1st. The company reported ($0.54) EPS for the quarter, hitting the consensus estimate of ($0.54). The business had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.25 million.

Kaleido Biosciences (KLDO) raised $101 million in an IPO on Thursday, February 28th 2019. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Shares of KLDO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kaleido Biosciences investors own include Editas Medicine (EDIT), Enovix (ENVX), COMPASS Pathways (CMPS), Rambus (RMBS), Luminar Technologies (LAZR), Precision BioSciences (DTIL) and Globant (GLOB).

Company Calendar

Last Earnings
11/01/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Computer Software
Current Symbol
NASDAQ:KLDO
Fax
N/A
Employees
76
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.10 million

Miscellaneous

Free Float
38,787,000
Market Cap
$6.39 million
Optionable
Not Optionable
Beta
-0.06
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

This page (NASDAQ:KLDO) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners